key: cord-0786880-gz3qdj6x authors: Kodam, Sai Priyanka; Ullah, Mujib title: Diagnostic and Therapeutic Potential of Extracellular Vesicles date: 2021-10-09 journal: Technol Cancer Res Treat DOI: 10.1177/15330338211041203 sha: aca2f71cf22763cafaed2e646df518278475367a doc_id: 786880 cord_uid: gz3qdj6x Extracellular vesicles (EVs) are naturally phospholipid enclosed nanovesicles released by many cells in the body. They are stable in circulation, have low immunogenicity, and act as carriers for functionally active biological molecules. They interact with target organs and bind to the receptors. Their target specificity is important to use EVs as noninvasive diagnostic and prognostic tools. EVs play a vital role in normal physiology and cellular communication. They are known to protect their cargo from degradation, which makes them important drug carriers for targeted drug delivery. Using EVs with markers and tracking their path in systemic circulation can be revolutionary in using them as diagnostic tools. We will discuss the scope of this in this paper. Although there are limitations in EVs isolation and storage, their high biocompatibility will fuel more innovations to overcome these challenges. After extraction from their natural environment, EVs are subjected to centrifugation to remove debris and dead cells. 30, 31 Using EV-compatible markers, they are separated into different types of EV pellets. 32 For use as markers in diagnostic imaging, biosensors are attached to track EVs in the systemic circulation. To be used as drug carriers, they are injected with specific medications. 27, 33, 34 After release from cells in their natural environment, there are mechanisms for cell-to-cell communication with adjacent tissues and distant organs. 35, 36 Given their role in biological communication between different tissues, they can serve as drug carriers for targeted therapy. 36, 37 EVs are able to transfer cytokines, bioactive compounds, miRNAs, and repair proteins in their cargo. 38, 39 They are effective in carrying the therapeutic cargo as they protect them from the surrounding environment. 40, 41 Tissue-specific receptors and biosensors can be lodged on the EVs for tracking the drug path. 38, 41, 42 The bioactive cargo of nanovesicles will increase the efficacy of drug delivery. 43, 44 The target specificity is useful in preventing drug penetration into other organs that can lead to systemic side effects. 44 The current concerns with EV therapeutic applications are, that the complete biochemical profile of EVs is not known. Further, there are no standardized isolation and purification methods, and the lack of efficient drug loading systems for clinical-grade production. 19, 45, 46 Multiple novel technologies have emerged in the past decade for EV isolation and characterization, but there is still a need for reproducible, cheap, and simpler alternatives that can be adapted for large-scale production. [46] [47] [48] Continuous attempts to develop more effective protocols are ongoing. 32, 49, 50 Isolation methods that are currently available include ultracentrifugation, filtration, size-exclusion chromatography, density gradient, and immunoaffinity-based isolation strategies. 51 Ultracentrifugation isolates the EVs by differential centrifugation. 51 Filtration uses membranes with specific pore sizes for different EVs. 51, 52 The isolated yield can be poor with this method. 43, 51 Size-exclusion chromatography uses the hydrodynamic column to reduce contamination, thus yielding a low EV output, but less protein contamination. 35, [53] [54] [55] Density gradient separates them based on density after initial isolation. 22, 54 Immune affinity-based isolation uses antibodies to capture EVs. 22, 56 This method is not a cost-effective approach. Table 1 . The current gold standard for EV isolation is "Ultracentrifugation-linked immunoprecipitation method." [56] [57] [58] This method yields smaller sized EVs with lesser apolipoprotein contamination, compared to other methods. 26, 59 The EVs need enrichment before processing. Currently, different labs have been using different preprocessing protocols. 60, 61 There is a need to develop an easily reproducible and standardized method. 61, 62 Table 1 . The newer technique size-exclusion chromatography purifies the EVs by removing the contaminating plasma proteins and high-density lipoproteins. 59, 63 It has been successfully used in the small-scale analysis of EVs. 63, 64 The column preparation, washing, and purification make it a time-consuming procedure. 64, 65 A novel membrane affinity spin column with better efficacy, ease, and reproducible workflow was released. The efficacy of purification using the new spin column is better compared to the optimized ultracentrifugation procedure, which is the current gold standard. 56 Using this method, EV isolation can be coupled with EV RNA extraction. 66, 67 This procedure captures nearly 100% mRNA. This provides a purified EV isolate without undesired protein-bound extracellular RNA co-precipitate. 67, 68 . 68, 69 The analysis of EV RNA is useful to understand the genetic markers of EVs. 70 The biggest advantage of EVs is the fact that they are composed of non-immunogenic substances. 70, 75 Therefore, the tissues do not identify the EVs as foreign, thus protecting their cargo from degradation. 52, 76 This makes it a safe method for drug delivery. 52, 77 The nano-size of EVs makes it one of the ideal carriers for the delivery of active molecules and drugs. 24, 78 They have successfully been applied for cancer therapy, inflammatory modulation, and immune response generation. [78] [79] [80] They can also be used to administer nutrients, minerals, and oxygen in stroke patients. 80, 81 This can reduce the recovery period and early rehabilitation of patients. 82, 83 Table 2 . Surface protein bioengineering, biosensor development, drug loading, coupled with placement of ligands on the surface of EVs reprogram EVs into smart multifunctional drug-loaded systems, 83, 84 Figure 1 . EVs are also used in imaging studies. 71, 85 The 2 major methods used in detecting EVs in the visible light spectrum are Bioluminescence imaging and fluorescence imaging. 86, 87 Bioluminescence imaging involves protein-based labeling and has a high signal-to-noise ratio as it is transmitted without any light source. 87, 88 An ultra-sensitive camera is needed to detect the EVs. 89 Fluorescence imaging uses organic dyes or protein to emit signals under excitation with an external light source. 90 Fluorescence is more easily detected by a charge coupled device camera. 91, 92 Imaging tools commonly used are single-photon emission computed tomography, positron emission tomography, and magnetic resonance imaging. [92] [93] [94] It should be remembered that the labeling compounds have a longer half-life than EVs and continue to be detected by imaging even after EVs are degraded. 54, 95 Bioengineering the EV membranes with inbuilt markers that degrade simultaneously with the EVs will be useful to avoid false-positive findings Table 2 . The protein and RNA cargo in the EVs associated with their cell of origin serve as molecular markers for screening a disease and to assess the progression. 40, 49, 96 The assays using highly purified EV samples will provide relevant clinical information. 40, 49, 96 Micro/nanofluidic technology with affinity capture for precise enrichment of EVs results in EVs that are highly purified compared to the conventional methods that isolate EVs irrespective of the cell of origin. 97, 98 Appropriate storage of EVs to maintain the stability of nucleic acids is essential. 37, 51 If these storage conditions are available, the EVs can most likely be used to diagnose gene mutations. 37, 51 Previous studies have proven that EVs and EV nucleic acids are stable in multiple environments. 37, 51, 74 The EVs and nucleic acids were relatively more stable at 4 degrees centigrade (up to 168 h and 1 week) compared to room temperature (up to 48 h and 1 day). 51, 74, 98 More studies to increase the shelf life of EVs in vitro and in vivo will surpass the current limitations to their use. 59 Preserving them with curcumin has been shown to increase the stability of EVs and potentiate the efficacy of the cargo. 58,99,100 Experimentation on additive substances or bioengineered isotopes to increase the stability can widen the diagnostic opportunities of EVs. Tables 1 and 2. EVs containing miRNAs and proteins perform a multitude of functions in target tissues. 101, 102 The structure, contents, and profiles of the cargo change with tissue damage to produce tissue regenerating substances. 57, 103 In heart failure, they mediate communication between cardiomyocytes and fibroblasts. 104 For example, MiR-146a-loaded EVs are released by endothelial cells during the development of peripartum cardiomyopathy. 105, 106 These MiR-146a-loaded EVs serve as biomarkers for diagnosis. 105, 106 Therefore, they can be used as tissue biomarkers and diagnostic tools in heart failure. 104 EVs are natural carriers of signaling molecules involved in atherosclerosis. 104, 107 Determining the types and their specific functional properties will be of relevance to discover biomarkers and alter the pathophysiology to control atherosclerosis. Cardiac progenitor cells (CPCs) and cardiosphere derived cells have shown promising results as useful tools in restoring heart function. 107 Unlike the EVs secreted from cardiomyocytes that have deleterious effects, EVs produced by CPCs are cardioprotective and mediate cardiogenesis. [107] [108] [109] They induce angiogenesis to reduce ischemic injury, infarct size, and inhibit apoptosis to prevent undesired remodeling. 110, 111 However, little is known how the EVs are produced in diseased and nondiseased cardiac tissues and the interaction of the EVs with the surrounding and distant tissues. 110 Further studies in these areas would be greatly beneficial to add to the current management of cardiovascular diseases. In mice, adipocyte-derived EVs in obese mice have been shown to activate differentiation of monocytes into macrophages, inducing insulin resistance. 112, 113 The same was not seen in lean mice. 114 Similarly, MiR and protein profiles of EVs from hypertensive rats were different from the normotensive rats. 115, 116 Further research to understand these differences can unfold the dynamic nature of EVs, Figure 1 . EVs in the neurons are the typical mode of communication between neurons and neuroglial cells. 117, 118 This interaction is important for the structural and functional integrity of the nervous system. 118 A lot of research has been done over the years to understand the molecular mechanisms involving the pathophysiology in neurodegenerative studies like Alzheimer's disease, 119, 120 Parkinson's disease, Huntington's disease, and other dementia disorders. [120] [121] [122] But the treatment modalities are still very limited. Research is underway to 33, 51, 64, 74 expand this in terms of newer medications, cell therapy, and gene therapy. As the EVs can cross blood-brain barrier, and are less immunogenic, studies increasingly suggest EVs as preferred vehicles for intracranial medication administration. 123 There are previous studies that show there is a high probability of association between EVs and Alzheimer's disease. 101, 117 Multiple studies have proven that the therapeutic effect of mesenchymal stem cells and adult stem cells is mostly due to their paracrine effect and not the direct action of these cells. 101, 124 Paracrine factors released by stem cells induce angiogenesis and modulate the immune response to exert the therapeutic effects. [125] [126] [127] Notably, the properties of purified mesenchymal stromal cells (MSC) derived EVs include most of the properties of mesenchymal cells itself. This provides an understanding that EVs from these cells are the major components involved in the disease process. 102, 127, 128 This property has been exploited to use the extracted EVs in multiple treatments Figure 1 . MSC-derived EVs in rat models with traumatic brain injury and ischemic brain injury has been shown to increase angiogenesis and neurogenesis, thus improving functional recovery. 129, 130 Katsuda et al. suggested a new treatment possibility using EVs that carry neprilysin, an amyloid degrading enzyme as a cell-free drug therapy for Alzheimer's disease, 131, 132 Figure 1 . EVs are secreted by the lining of the respiratory tract similar to any other cell in the body and their role in the pathogenesis of lung diseases has been established in previous studies. 133, 134 Recent studies show that EVs and viruses are interdependent on each other for cellular entry and exit owing to their similar physicochemical properties, for example, size and heterogeneous size distribution. 134 Therefore, trials using EVs loaded with antiviral medications to block viral intracellular entry can be explored. In the past 1 year, mesenchymal stem cell (MSCs) therapy for SARS-CoV-2 infection is being explored in multiple studies. 135, 136 MSCs have unique potential for immunomodulation, antiviral defense, and tissue regeneration. Umbilical cordderived MSCs have shown promising results in smaller studies. 137, 138 They induce the production of cytokines, paracrine factors that interact with immune cells to stimulate vascular endothelial growth factor, epidermal growth factor, transforming growth factor release mediated tissue regeneration. 139, 140 The promising tissue regenerative properties of MSC-derived EVs support pulmonary tissue regeneration post coronavirus 2019 (COVID- 19) illness. The limitations with MSC use are shorter half-life, lasting a few minutes in the blood stream. MSCs derived from embryogenic tissue can be mutagenic and tumorgenic. 141, 142 Intravenous administration of MSCs can cause platelet aggregation and thrombogenesis leading to emboli. 142 EVs derived from MSCs can be administered via intranasal and inhalational route, contributing to lesser immunogenic or thrombogenic side effects. 143, 144 They do not enter the circulation where they can be lost in a few minutes and do not cause thrombus formation. [145] [146] [147] They do not self-replicate like MSCs, therefore are less tumorigenic. 148, 149 EVs can be administered along with antiviral drugs. 150, 151 Preliminary studies suggest that co-treatment with EVs obtained from mesenchymal cell secretomes is effective in treating COVID-19 patients. 135, 136, 151 Further preclinical data considering safety, ethics, and practicality is needed to adapt this regimen for COVID-19 treatment. EVs show great promise as diagnostic and therapeutic markers in many diseases. There is a dire need to work on standardization of isolation and storage methods of EVs. This will enable a wider Neurological illnesses Nutrient administration and oxygen supply to the ischemic tissues in stroke. Angiogenesis and neurogenesis in traumatic brain injury observed in rat models. Further studies to determine their effects on the human nervous system are needed. 3, 8, 37, 105, 106, 110, 111, 121, 122, 134, 141, 152 Pulmonary diseases EVs derived from MSCs can be used for immunomodulation, viral defense, and tissue regeneration The evidence has been shown in smaller studies with <50 patients. Larger studies are needed to adapt these treatments 129, 134, 138, 141 application of EVs in large-scale treatment trials. Several studies have shown that the current methods available have limitations like contamination of samples, cost issues, instability issues, among others. Ultracentrifugation with immunoprecipitation has been a promising method. If the preprocessing methods are standardized and ways to curb the cost factor are explored. This method can be adapted for therapeutic EV production as it produces highly selective EVs. Further studies are urgently needed to explore these methods which can pave the path for the clinical application of EVs. The pathological processes in which the EVs are being applied show great benefits with minimal side effects. As EVs are derived from human cells, there is always the benefit of biocompatibility compared to other modalities of treatment. In addition to cardiovascular and neurological diseases, the need of the hour is the treatment of SARS-CoV-2 infection. Though the studies so far for EVs derived from MSCs in COVID illness have been small, there is a great scope as they offer a combination of benefits providing immunomodulatory function, viral defense, and tissue regeneration. This can decrease the severity and duration of COVID-19 illness. Further studies in this area are needed. The regenerative property can also be utilized for cardiac remodeling in post-MI patients, neuroregeneration in stroke patients, thus decreasing the morbidity and mortality. Stem cell-derived extracellular vesicles: role in oncogenic processes, bioengineering potential, and technical challenges Extracellular vesicle-associated proteins in tissue repair Extracellular vesicle membrane-associated proteins: emerging roles in tumor angiogenesis and antiangiogenesis therapy resistance Extracellular vesicles mediate B cell immune response and are a potential target for cancer therapy The contrasting role of extracellular vesicles in vascular inflammation and tissue repair Figure 1. Schematic illustration showing the application of extracellular vesicles in different diseases A system of cytokines encapsulated in extraCellular vesicles Extracellular vesicles, exosomes and shedding vesicles in regenerative medicine-a new paradigm for tissue repair Emerging role of extracellular vesicles in inflammatory diseases Transfer of extracellular vesicles during immune cell-cell interactions Classification, functions, and clinical relevance of extracellular vesicles Exosomes in therapy: engineering, pharmacokinetics and future applications Exosome theranostics: biology and translational medicine Reprogramming exosomes as nanoscale controllers of cellular immunity Circulating exosomes in cardiovascular disease: novel carriers of biological information Live tracking of inter-organ communication by endogenous exosomes In vivo Communication by extracellular vesicles: where we are and where we need to go Exosomes in the tumor microenvironment as mediators of cancer therapy resistance Development and MPI tracking of novel hypoxia-targeted theranostic exosomes Microbubbles versus extracellular vesicles as therapeutic cargo for targeting drug delivery Visualization of exosomes from mesenchymal stem cells in vivo by magnetic resonance imaging Advances in imaging strategies for in vivo tracking of exosomes Stem cellderived extracellular vesicles mitigate ageing-associated arterial stiffness and hypertension Biological properties of extracellular vesicles and their physiological functions Extracellular vesicles: biology and emerging therapeutic opportunities Shedding light on the cell biology of extracellular vesicles New technologies for analysis of extracellular vesicles Clinical relevance of RNA editing to early detection of cancer in human Apoptotic bodies: selective detection in extracellular vesicles Extracellular vesicles: emerging targets for cancer therapy Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes A novel mechanism of generating extracellular vesicles during apoptosis via a beads-on-a-string membrane structure Extracellular vesicle heterogeneity: subpopulations, isolation techniques, and diverse functions in cancer progression Extracellular vesicle isolation and characterization: toward clinical application Applications of artificial intelligence in, early detection of cancer, clinical diagnosis and personalized medicine Biomaterial-based extracellular vesicle delivery for therapeutic applications Clinical applications of extracellular vesicle long RNAs Emerging role of stem cell-derived extracellular microRNAs in age-associated human diseases and in different therapies of longevity Strategic design of extracellular vesicle drug delivery systems Extracellular vesicle long non-coding RNAs and circular RNAs: biology, functions and applications in cancer RNA Delivery by extracellular vesicles in mammalian cells and its applications Extracellular vesicle transfer of cancer pathogenic components An emerging role of CD9 in stemness and chemoresistance From laboratory to clinic: translation of extracellular vesicle based cancer biomarkers Drug delivery with extracellular vesicles: from imagination to innovation Promising extracellular vesicle-based vaccines against viruses, including SARS-CoV-2 Engineering exosomes for targeted drug delivery Heat shock protein 20 promotes sirtuin 1-dependent cell proliferation in induced pluripotent stem cells Artificial intelligence and guidance of medicine in the bubble A novel approach to deliver therapeutic extracellular vesicles directly into the mouse kidney via its arterial blood supply iPS-derived MSCs from an expandable bank to deliver a prodrug-converting enzyme that limits growth and metastases of human breast cancers Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications The function and clinical application of extracellular vesicles in innate immune regulation Mesenchymal stromal/ stem cell-derived extracellular vesicles in tissue repair: challenges and opportunities AR: technologies and standardization in research on extracellular vesicles Extracellularvesicle isolation from different biological fluids by size-exclusion chromatography Chromatographic approaches for purification and analytical characterization of extracellular vesicles: recent advancements extracellular vesicles as biological shuttles for targeted therapies DRF: the challenges and possibilities of extracellular vesicles as therapeutic vehicles Rapid isolation and enrichment of extracellular vesicle preparations using anion exchange chromatography Evaluation of serum extracellular vesicle isolation methods for profiling miRNAs by next-generation sequencing Updating the MISEV minimal requirements for extracellular vesicle studies: building bridges to reproducibility Quality and efficiency assessment of six extracellular vesicle isolation methods by nano-flow cytometry Extracellular vesicle isolation methods: rising impact of size-exclusion chromatography Reproducible and scalable purification of extracellular vesicles using combined bind-elute and size exclusion chromatography Exosome isolation and purification via hydrophobic interaction chromatography using a polyester, capillary-channeled polymer fiber phase Evaluation of optimal extracellular vesicle small RNA isolation and qRT-PCR normalisation for serum and urine Detection of extracellular vesicle RNA using molecular beacons. iScience Emerging technologies in extracellular vesicle-based molecular diagnostics Mesenchymal stem cells confer chemoresistance in breast cancer via a CD9 dependent mechanism Focus on extracellular vesicles: development of extracellular vesicle-based therapeutic systems Imaging extracellular vesicles: current and emerging methods Overview and update on methods for cargo loading into extracellular vesicles. Processes (Basel) Perspectives of microscopy methods for morphology characterisation of extracellular vesicles from human biofluids Methods and technologies for exosome isolation and characterization Extracellular vesicle-based nanotherapeutics: emerging frontiers in anti-inflammatory therapy Regulation of immune responses by extracellular vesicles MSC-derived extracellular vesicles attenuate immune responses in two autoimmune murine models: type 1 diabetes and uveoretinitis Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes Comparative marker analysis of extracellular vesicles in different human cancer types Extracellular vesicles: a new communication paradigm? Clinical applications of extracellular vesicles in the diagnosis and treatment of traumatic brain injury Inflammation-Stimulated mesenchymal stromal cell-derived extracellular vesicles attenuate inflammation Bioinspired extracellular vesicles: lessons learned from nature for biomedicine and bioengineering Stem cell extracellular vesicles: extended messages of regeneration Extracellular vesicles in the oviduct: progress, challenges and implications for the reproductive success Quantification of extracellular vesicles in vitro and in vivo using sensitive bioluminescence imaging Illuminating the physiology of extracellular vesicles A new bioluminescent reporter system to study the biodistribution of systematically injected tumor-derived bioluminescent extracellular vesicles in mice Emerging strategies for labeling and tracking of extracellular vesicles 3D Tracking of extracellular vesicles by holographic fluorescence imaging Phenotypic analysis of extracellular vesicles: a review on the applications of fluorescence An update on in vivo imaging of extracellular vesicles as drug delivery vehicles Iron oxide labeling and tracking of extracellular vesicles Radiolabelling of extracellular vesicles for PET and SPECT imaging Current perspectives on in vivo noninvasive tracking of extracellular vesicles with molecular imaging Exploring the utility of extracellular vesicles in ameliorating viral infection-associated inflammation, cytokine storm and tissue damage Nanoplasmonic exosome diagnostics Exosome isolation: a microfluidic road-map Co-delivery of curcumin and miRNA-144-3p using heart-targeted extracellular vesicles enhances the therapeutic efficacy for myocardial infarction Prospective therapeutic applications of platelet extracellular vesicles Targeting and crossing the blood-brain barrier with extracellular vesicles Need for specialized therapeutic stem cells banks equipped with tumor regression enzymes and anti-tumor genes Extracellular vesicles for drug delivery Klotho deficiency causes heart aging via impairing the Nrf2-GR pathway Role of extracellular vesicles and microRNAs on dysfunctional angiogenesis during preeclamptic pregnancies Extracellular vesicles in cardiovascular diseases Cardiac recovery via extended cell-free delivery of extracellular vesicles secreted by cardiomyocytes derived from induced pluripotent stem cells Beneficial effects of exosomes secreted by cardiac-derived progenitor cells and other cell types in myocardial ischemia Cardioprotective microRNAs: lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease Therapeutic angiogenesis using stem cell-derived extracellular vesicles: an emerging approach for treatment of ischemic diseases Extracellular vesicles as new players in angiogenesis Human adipocyte extracellular vesicles in reciprocal signaling between adipocytes and macrophages Effects of exosomes from LPS-activated macrophages on adipocyte gene expression, differentiation, and insulin-dependent glucose uptake Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity Plasma exosomes regulate systemic blood pressure in rats Plasma small extracellular vesicles in hypertensive rats impair reactivity of isolated blood vessels Extracellular vesicles and a novel form of communication in the brain Extracellular vesicles round off communication in the nervous system Focus on extracellular vesicles: exosomes and their role in protein trafficking and biomarker potential in Alzheimer's and Parkinson's disease The role of extracellular vesicles in the progression of neurodegenerative disease and cancer Extracellular vesicles-their role in the packaging and spread of misfolded proteins associated with neurodegenerative diseases Extracellular vesicles in neurodegenerative diseases The transport mechanism of extracellular vesicles at the blood-brain barrier Reversing acute kidney injury using pulsed focused ultrasound and MSC therapy: a role for HSP-mediated PI3K/AKT signaling Stem cell differentiation requires a paracrine pathway in the heart HSP70-mediated NLRP3 inflammasome suppression underlies reversal of acute kidney injury following extracellular vesicle and focused ultrasound combination therapy Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair The role of ultrasound in enhancing mesenchymal stromal cell-based therapies microRNA-130b-3p contained in MSC-derived EVs promotes lung cancer progression by regulating the FOXO3/NFE2L2/TXNRD1 axis Extracellular vesicles: pathogenetic, diagnostic and therapeutic value in traumatic brain injury Potential application of extracellular vesicles of human adipose tissue-derived mesenchymal stem cells in Alzheimer's disease therapeutics Human adipose tissuederived mesenchymal stem cells secrete functional neprilysinbound exosomes Crucial role of extracellular vesicles in bronchial asthma The emerging role of small extracellular vesicles in inflammatory airway diseases The pandemic of novel coronavirus disease 2019 (COVID-19): need for an immediate action Novel coronavirus (COVID-19) treatment options Hill AF: iSEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19 Can stem cells beat COVID-19: advancing stem cells and extracellular vesicles toward mainstream medicine for lung injuries associated with SARS-CoV-2 infections Unraveling the mesenchymal stromal cells' paracrine immunomodulatory effects The immunomodulatory functions of mesenchymal stromal/stem cells mediated via paracrine activity Stem cells and cell therapies in lung biology and lung diseases Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells Intranasal delivery of stem cells as therapy for central nervous system disease The route by which intranasally delivered stem cells enter the central nervous system Intranasal stem cell treatment as a novel therapy for subarachnoid hemorrhage Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage Intranasal delivery of stem cells to the brain Future perspectives on the role of stem cells and extracellular vesicles in vascular tissue regeneration Extracellular vesicles and their roles in stem cell biology Repurposing antiviral protease inhibitors using extracellular vesicles for potential therapy of COVID-19 Inhibiting extracellular vesicle trafficking as antiviral approach to corona virus disease 2019 infection Potential roles of extracellular vesicles in the pathophysiology, diagnosis, and treatment of autoimmune diseases The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The authors received no financial support for the research, authorship and/or publication of this article. https://orcid.org/0000-0003-0168-8700